Flimabo 100 mg/g Suspension for Use in Drinking Water for Chickens and Pigs

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: VMD (Veterinary Medicines Directorate)

Aktif bileşen:

Flubendazole

Mevcut itibaren:

Krka d.d., Novo Mesto

ATC kodu:

QP52AC12

INN (International Adı):

Flubendazole

Farmasötik formu:

Oral suspension

Reçete türü:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Terapötik grubu:

Chickens, Pigs

Terapötik alanı:

Anthelmintic

Yetkilendirme durumu:

Authorized

Yetkilendirme tarihi:

2013-07-18

Ürün özellikleri

Revised: November 2017
AN: 00620/2017
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
FLIMABO 100 mg/g suspension for use in drinking water for chickens and
pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each g contains:
ACTIVE SUBSTANCE:
Flubendazole
100 mg
EXCIPIENTS:
Methyl parahydroxybenzoate (E218)
2.0 mg
Sodium benzoate (E211)
5.0 mg
Disodium edetate
0.1 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for use in drinking water.
White to brownish white suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs (piglets, pigs for fattening, pregnant and lactating sows) and
chickens (layer hens,
chickens for reproduction, pullets, broilers).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In hens/chickens:
Treatment of helminthiasis caused by _Ascaridia galli_ (adult stages),
_Heterakis gallinarum _
(adult stages), _Capillaria _spp. (adult stages).
In pigs:
Treatment of helminthiasis caused by _Ascaris suum_ (adult and
intestinal larval stages) in
piglets, fattening pigs, pregnant and lactating sows.
4.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
In chickens, optimal results can only be achieved if strict rules of
hygiene are respected
in the maintenance of the cages.
Revised: November 2017
AN: 00620/2017
Page 2 of 7
In both species:
Care should be taken to avoid the following practices because they
increase the risk of
development of resistance and could ultimately result in ineffective
therapy:
• Too frequent and repeated use of anthelmintics from the same
class, over an extended
period of time.
• Underdosing, which may be due to underestimation of body weight,
misadministration
of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be
further investigated
using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where
t